Q1 Earnings Forecast for CGEM Issued By HC Wainwright

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Cullinan Therapeutics in a report released on Wednesday, January 29th. HC Wainwright analyst E. White expects that the company will post earnings of ($0.80) per share for the quarter. HC Wainwright has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Cullinan Therapeutics’ Q2 2025 earnings at ($0.84) EPS and Q3 2025 earnings at ($0.90) EPS.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.09.

Separately, UBS Group initiated coverage on Cullinan Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $30.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $32.50.

Cullinan Therapeutics Price Performance

Cullinan Therapeutics stock opened at $10.56 on Friday. The stock’s fifty day moving average price is $11.70 and its two-hundred day moving average price is $15.19. The firm has a market cap of $614.91 million, a PE ratio of -3.72 and a beta of -0.14. Cullinan Therapeutics has a one year low of $9.50 and a one year high of $30.19.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Squarepoint Ops LLC bought a new stake in Cullinan Therapeutics during the 2nd quarter worth $186,000. The Manufacturers Life Insurance Company grew its holdings in shares of Cullinan Therapeutics by 40.7% during the second quarter. The Manufacturers Life Insurance Company now owns 15,175 shares of the company’s stock worth $265,000 after purchasing an additional 4,393 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in shares of Cullinan Therapeutics by 18.3% in the third quarter. Assenagon Asset Management S.A. now owns 135,036 shares of the company’s stock valued at $2,261,000 after buying an additional 20,841 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of Cullinan Therapeutics by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,151 shares of the company’s stock valued at $187,000 after buying an additional 4,380 shares during the period. Finally, Harbor Capital Advisors Inc. raised its holdings in Cullinan Therapeutics by 22.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 21,362 shares of the company’s stock valued at $358,000 after buying an additional 3,881 shares during the last quarter. 86.31% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Nadim Ahmed sold 8,400 shares of the stock in a transaction that occurred on Tuesday, December 24th. The shares were sold at an average price of $11.87, for a total value of $99,708.00. Following the completion of the transaction, the chief executive officer now owns 263,150 shares of the company’s stock, valued at $3,123,590.50. This represents a 3.09 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jennifer Michaelson sold 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $15.64, for a total transaction of $125,120.00. Following the completion of the sale, the insider now owns 107,942 shares in the company, valued at $1,688,212.88. This represents a 6.90 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,582 shares of company stock worth $372,097. Insiders own 6.07% of the company’s stock.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.